and is expected to impact over 4 billion people globally by 2035 Basel, 12 March 2025 - Roche (SIX: RO, ROG; The new center will be a hub for both Roche and Genentech, bringing together expertise ...

Roche announced that it has struck an exclusive deal with Denmark's Zealand Pharma to develop and market petrelintide, a new treatment for obesity.

Pharmaceutical giant Roche announces opening of an innovation centre at Harvard University's corporate research campus.

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...

U.S. President Donald Trump’s threats to impose tariffs on medicines could rattle an industry that has become a cornerstone ...

Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal ...

Dividend Yield as of February 6: 3.33% Number of Hedge Fund Holders: N/A Roche Holding AG (OTC:RHHBY) was established in 1896 and is headquartered in Basel, Switzerland. The company develops ...

Roche will be the first to join Harvard's Enterprise Research Campus in Allston, taking a suite in the first phase of the ...

Our AVENIO assays offer robust solutions for oncology, including the recent approval of the AVENIO Tumor Tissue CGP Automated Kit, a collaboration between Roche and Foundation Medicine, two leaders in ...

Gazyva/Gazyvaro is an anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus ...